JPRN-UMIN000006159已完成2 期
Phase II trial of Trastuzumab in combination with Abraxane for patients with HER2-positive metastatic breast cancer - Trastuzumab/Abraxane for HER2-positive MBC
Kumamoto Breast Cancer Cooperative Group0 个研究点目标入组 23 人开始时间: 2011年8月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •(1)With history of hypersensitivity reaction for trastuzumab, paclitaxel and albumin (2)With severe complication. (3)Pregnant or nursing women. (4)With widespread liver metastases or pulmonary lymphangitis with dyspnea (5) with active another cancer (6)with brain metastasis with symptom (7)with uncontrollable hypertension, angina pectoris, congestive heart failure, myocardial infection within 1 year, arrhythmia that need treat, valvular heart disease. (8)with pulmonary fibrosis or pneumonitis. (9)with dyspnea at rest (due to metastatic lung lesion and cardiovascular disease). (10)with pleural effusion, ascites, and pericardial effusion that need treat (11) Cases who physician judged improper to entry this trial
研究者
相似试验
进行中（未招募）
1 期
Study of trastuzumab in combination with pertuzumab in patients already treated with a lung cancer harboring a Her2 mutation and receiving docetaxelon small cell lung cancer with a Her2 mutationMedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10075653Term: HER2 gene amplificationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-003506-11-FRIFCT45
已完成
2 期
Randomized phase II trial evaluating trastuzumab + capecitabine (HX) or lapatinib + capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanesHER2-positive metastatic breast cancerJPRN-UMIN000005219West Japan Oncology Group110
招募中
不适用
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancerNeoplasmsKCT0004391Asan Medical Center28
进行中（未招募）
2 期
A phase II clinical trial examining trastuzumab biosimilar (CT-P6) and chemotherapy (oxaliplatin +S-1 or oxaliplatin +Capecitabine) for treatment of HER2-positive advanced/recurrent gastric cancer previously untreated with chemotherapyGastric CancerJPRN-jRCTs071190007Oki Eiji68
已完成
2 期
Phase II trial of Trastuzumab + CPT-11 therapy for HER2-positive advanced gastric cancer patients with prior chemotherapyAdvanced Gastric CancerJPRN-UMIN000008626Osaka Gastrointestinal cancer chemotherapy Study Group (OGSG)30